+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

CAR-T Label Update Could Address Medicare Coverage Challenges, FDA's Gottlieb Suggests

  • PDF Icon

    Newsletter

  • 3 Pages
  • June 2024
  • Region: Global
  • Citeline
  • ID: 4775330
US FDA Commissioner Scott Gottlieb said at a recent policy conference that chimeric antigen receptor T-cell (CAR-T) therapies may soon be relabeled for outpatient use, easing the cost of these new therapies for providers, while furnishing coverage under the Medicare Part B plan.

Find out more about the financial concerns for CAR-T therapies, the impact that outpatient CAR-T therapies would have on Medicare c. and what it means for both providers and for Medicare, in this essential article from Pink Sheet.